A2AR were inhibited using istradefylline (KW-6002), the first adenosine A2AR antagonist that has been approved clinically for the treatment of l-DOPA-resistant patients with Parkinson’s disease [21,22,23]. The gene discussed is ADORA2A; the disease is Parkinson disease.